Floatz logo
Floatz Rating
BB68/100
Confidence
Indicative
v0.2
Sponsor
Novo Nordisk A/S
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07023029CT.gov
A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants
—Completed———
NCT06609226CT.gov
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
—Recruiting———
NCT06581627CT.gov
A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants
—Completed———
NCT04987489CT.gov
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Thalassemia

AssetSponsorPhaseRating
Etavopivat (this asset)Novo Nordisk A/SP3BB · 68
DeferasiroxNovartis PharmaceuticalsP4BBB
HydroxyureaRiphah International UniversityP4BB
FludarabineMemorial Sloan Kettering Cancer CenterP2/3BB
Zinc SulfateFakultas Kedokteran Universitas IndonesiaP4BB
BusulfanumUniversity of California, San FranciscoP2/3BB
Ppsv23Fakultas Kedokteran Universitas IndonesiaP4BB
Conjugated Pneumococcal VaccineFakultas Kedokteran Universitas IndonesiaP4BB
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene TranscriptionVertex Pharmaceuticals IncorporatedP3BB

+42 more in the Thalassemia cohort

Other indications for Etavopivat

IndicationSponsorPhaseRating
Sickle Cell Disease—P3B · 60

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Etavopivat in Thalassemia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/etavopivat-thalassemia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →